Table 1.

Summary of serostatus of mother-infant pairs (all mother-infant pairs with serology data)^a

HPV type	cLIA				IgG assay
	n	Mother's serostatusb	Infant's serostatusb		n	Mother's serostatusc	Infant's serostatusc
			Positive m (%d)	Negative m (%d)			Positive m (%d)	Negative m (%d)
6	24	Positive	16 (66.7)	4 (16.7)	13	Positive	11 (84.6)	0 (0.0)
		Negative	1 (4.2)	3 (12.5)		Negative	2 (15.4)	0 (0.0)
11	24	Positive	20 (83.3)	0 (0.0)	14	Positive	9 (64.3)	0 (0.0)
		Negative	1 (4.2)	3 (12.5)		Negative	3 (21.4)	2 (14.3)
16	24	Positive	22 (91.7)	1 (4.2)	14	Positive	14 (100)	0 (0.0)
		Negative	0 (0.0)	1 (4.2)		Negative	0 (0.0)	0 (0.0)
18	23	Positive	9 (39.1)	1 (4.3)	13	Positive	8 (61.5)	0 (0.0)
		Negative	0 (0.0)	13 (56.5)		Negative	3 (23.1)	2 (15.4)

^aAbbreviations: n, number of mother-infant pairs contributing to the analysis; m, number of mother-infant pairs with the indicated serostatus; cLIA, competitive Luminex immunoassay.

^bSerostatus positive (negative) for HPV-6, -11, -16, and -18 is defined as HPV cLIA values of ≥ (<) 20, 16, 20, and 24 mMU/ml, respectively.

^cSerostatus positive (negative) for HPV-6, -11, -16, and -18 is defined as HPV IgG values of ≥ (<) 15, 15, 9, and 14 mMU/ml, respectively.

^dPercent is calculated as 100 × (m/n).